Advanced BioMedical Technologies, Inc. operates as an investment holding company with interests in manufacturing and distributing electro-acuscope and electro-myopulse instruments. Its products include Polymer Osteosynthesis Devices made of a proprietary material compositing of polyamide 6, hydroxyapatite and poly(methyl methacrylate-co-N-vinylpyrrolidone). The company was founded in 1984 and is headquartered in New York.
Company profile
Ticker
ABMT
Exchange
Website
CEO
Hui Wang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • STERIS • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
Former names
Geostar Mineral CORP
SEC CIK
IRS number
980516589
ABMT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
27 Jan 22
10-Q
2021 Q3
Quarterly report
13 Sep 21
10-Q
2021 Q2
Quarterly report
21 Jun 21
NT 10-Q
Notice of late quarterly filing
14 Jun 21
10-Q
2021 Q1
Quarterly report
22 Mar 21
NT 10-Q
Notice of late quarterly filing
17 Mar 21
10-K
2020 FY
Annual report
29 Jan 21
10-Q
2020 Q3
Quarterly report
21 Sep 20
NT 10-Q
Notice of late quarterly filing
14 Sep 20
Latest ownership filings
4
Change in insider ownership
1 Nov 21
4
Change in insider ownership
1 Nov 21
4
Change in insider ownership
6 Oct 21
4
Change in insider ownership
10 Nov 20
4
Change in insider ownership
10 Nov 20
3
Initial statement of insider ownership
9 Mar 20
4
Change in insider ownership
9 Mar 20
4
Change in insider ownership
9 Mar 20
4
Change in insider ownership
25 Oct 18
4
Change in insider ownership
25 Oct 18
Financial summary
Quarter (USD) | Jul 21 | Apr 21 | Jan 21 | Oct 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 20 | Oct 19 | Oct 18 | Oct 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.98 k | 6.98 k | 6.98 k | 6.98 k | 6.98 k | 6.98 k |
Cash burn (monthly) | (no burn) | 624.25 | 66.24 k | 62.77 k | 26.99 k | (no burn) |
Cash used (since last report) | n/a | 23.56 k | 2.50 mm | 2.37 mm | 1.02 mm | n/a |
Cash remaining | n/a | -16.57 k | -2.49 mm | -2.36 mm | -1.01 mm | n/a |
Runway (months of cash) | n/a | -26.5 | -37.6 | -37.6 | -37.5 | n/a |